Abstract
This study attempted to determine whether human leukocyte antigen (HLA) type changes would be caused by lithium. A total of 15 patients were chosen as subjects (4 males, 11 females) and completed tests in class I. Eight of the 15 patients completed tests in class II. Their mean age was 27 +/- 7 years. For an average of 51 +/- 17 days, lithium, 600-1,200 mg/day (mean daily dose: 920 +/- 211 mg) was administered for the HLA testing and then compared with the HLA type prior to the time the drug was administered. Class I type test was performed according to the Terasaki microcytotoxicity method and class II type by the Erlich polymerase chain reaction method. Of the 15 subjects, 11 had changes in HLA-A, B, C types and two of the eight subjects had changes in HLA DR type. Lithium, in the therapeutic dose, is considered to bring about changes in HLA expressions in as short a time period as 2 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
